Bulk Pharmaceutical API Sources for MACROBID

Bulk Pharmaceutical API Sources for MACROBID

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemBridge		5492202
Sigma-Aldrich		N7878_SIGMA
Molport		MolPort-001-018-217
AKos Consulting & Solutions		AKOS001678301
Vitas-M Laboratory		STK009471
TCI (Tokyo Chemical Industry)		N0883
Amadis Chemical		A835659

MACROBID Bulk Active Pharmaceutical Ingredient (API) Sourcing

Last updated: February 19, 2026

This report analyzes bulk Active Pharmaceutical Ingredient (API) sourcing for Macrobid, a brand-name prescription drug containing nitrofurantoin. The analysis focuses on key API manufacturers, patent landscape, regulatory considerations, and market dynamics relevant to R&D and investment decisions.

What is Macrobid and its API?

Macrobid is a urinary tract infection (UTI) treatment. Its active pharmaceutical ingredient is nitrofurantoin, a synthetic antibacterial agent. Nitrofurantoin is available in two forms: a monohydrate crystal form and a macrocrystalline crystal form. Macrobid specifically utilizes nitrofurantoin macrocrystals, which are designed for slower release and potentially reduced gastrointestinal side effects compared to the monohydrate form.

Nitrofurantoin macrocrystals are synthesized through a controlled crystallization process. The manufacturing process involves dissolving nitrofurantoin monohydrate in a suitable solvent system and then inducing precipitation under specific temperature and agitation conditions to form larger, more uniform macrocrystals. The particle size distribution and crystalline morphology are critical quality attributes influencing dissolution rate and bioavailability [1].

Key API Manufacturers

Several global pharmaceutical ingredient manufacturers produce nitrofurantoin API. The selection of a supplier involves evaluating manufacturing capacity, quality control systems, regulatory compliance, and cost.

The following table lists prominent nitrofurantoin API manufacturers:

Manufacturer Name	Country of Origin	Key Product Offering	Notes
Zhejiang NHU Co., Ltd.	China	Nitrofurantoin Monohydrate, Nitrofurantoin Macrocrystals	A major global supplier of APIs with significant production capacity.
Aurobindo Pharma Ltd.	India	Nitrofurantoin Monohydrate, Nitrofurantoin Macrocrystals	A vertically integrated pharmaceutical company with a strong API manufacturing base.
Granules India Ltd.	India	Nitrofurantoin Monohydrate, Nitrofurantoin Macrocrystals	Focuses on producing high-quality APIs for regulated markets.
IOL Chemicals and Pharmaceuticals Ltd.	India	Nitrofurantoin Monohydrate, Nitrofurantoin Macrocrystals	Offers a range of pharmaceutical intermediates and APIs.
Sanofi	France	Nitrofurantoin (primarily as finished dosage form, API sourcing varies)	While Sanofi is the brand owner of Macrodantin and Macrobid, their API sourcing strategy is complex and may involve internal production or contract manufacturing organizations.
Teva Pharmaceutical Industries Ltd.	Israel	Nitrofurantoin (API for generics)	A significant player in the generic pharmaceutical market, requiring robust API supply chains.

Source: Company reports, industry databases, and trade publications. Specific production volumes are proprietary.

Manufacturing Capacity and Scale

Manufacturing capacity for nitrofurantoin API is distributed globally, with a significant concentration in India and China. These regions benefit from established chemical manufacturing infrastructure and competitive production costs. Companies like Zhejiang NHU and Aurobindo Pharma have demonstrated capabilities to produce nitrofurantoin at scale, meeting the demands of both branded and generic drug manufacturers.

The production of nitrofurantoin macrocrystals requires specialized crystallization technology to achieve the desired particle size and morphology. Manufacturers must adhere to strict Good Manufacturing Practices (GMP) to ensure API purity, potency, and consistency.

Patent Landscape for Nitrofurantoin API and Formulations

The patent landscape for nitrofurantoin, particularly its macrocrystalline form, is crucial for understanding market exclusivity and generic entry. While the core molecule of nitrofurantoin has been known for decades and is off-patent, patents have been granted for novel formulations, manufacturing processes, and specific crystalline forms.

Key Patent Considerations

• Process Patents: Patents may cover specific methods of synthesizing nitrofurantoin macrocrystals, focusing on steps like solvent selection, crystallization temperature, seeding, and drying. These patents can create barriers to entry for new API manufacturers attempting to replicate a specific manufacturing process.
• Formulation Patents: Patents can protect novel drug delivery systems or specific combinations of nitrofurantoin with excipients that enhance stability, bioavailability, or reduce side effects. Macrobid's success is partly attributed to its macrocrystalline formulation, which aims for improved patient tolerance.
• Polymorph Patents: While less common for established molecules, patents can sometimes be granted for specific crystalline forms (polymorphs) of an API if they demonstrate advantageous properties. The macrocrystalline form of nitrofurantoin is a distinct physical form with different characteristics than the monohydrate.

Example of Patent Focus:

Early patents for nitrofurantoin itself date back to the mid-20th century. However, subsequent patenting activity has focused on:

• US Patent 4,432,981 (Expired): This patent, assigned to Richardson-Merrell, Inc. (later to become part of Sanofi-Aventis), disclosed and claimed nitrofurantoin macrocrystals. This patent was foundational for the development of Macrodantin and Macrobid. The patent expired in the early 2000s, opening the door for generic competition for the specific macrocrystalline formulation.
• Manufacturing Process Patents: Numerous patents have been filed and granted globally detailing specific methods for producing nitrofurantoin macrocrystals. These can include variations in crystallization parameters, purification techniques, and drying methods. Analyzing these patents is vital for understanding potential infringement risks for new manufacturers.

The expiration of key formulation and process patents for nitrofurantoin macrocrystals has significantly influenced the market, leading to the introduction of generic versions. However, ongoing patent filings related to novel synthetic routes, improved purification methods, or new salt forms could still present opportunities or challenges.

Regulatory Compliance and Quality Standards

API sourcing for pharmaceuticals requires adherence to stringent regulatory guidelines enforced by health authorities worldwide.

Key Regulatory Aspects

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP standards. These regulations ensure that APIs are consistently produced and controlled according to quality standards appropriate for their intended use. Key regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA).
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains detailed information about the manufacturing process, facility, quality control, and stability of the API. Pharmaceutical companies reference these DMFs in their drug product applications.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides guidelines on quality, safety, efficacy, and multidisciplinary topics. Adherence to ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients) is essential.
• Impurity Profiling: Manufacturers must rigorously control and report any impurities present in the API. This includes genotoxic impurities, heavy metals, residual solvents, and degradation products. Analytical methods for impurity detection and quantification must be validated.
• Supply Chain Security: Ensuring the integrity and security of the API supply chain is critical to prevent counterfeiting and contamination. This involves audits of suppliers, secure transportation, and robust inventory management.

FDA Inspection and Compliance: Manufacturers supplying API for drugs sold in the United States must be prepared for FDA inspections. A history of successful inspections and compliance with FDA regulations is a significant indicator of a reliable supplier.

Market Dynamics and Supply Chain Considerations

The market for nitrofurantoin API is influenced by factors such as demand for finished dosage forms, pricing, competitive landscape, and global supply chain stability.

Demand Drivers

• Prevalence of UTIs: Urinary tract infections are common, driving consistent demand for effective treatments like Macrobid and its generic equivalents.
• Antibiotic Resistance: As antibiotic resistance patterns evolve, older, effective antibiotics like nitrofurantoin remain important treatment options, particularly for uncomplicated UTIs.
• Generic Competition: The availability of generic nitrofurantoin macrocrystals has increased market access and price competition, influencing API pricing.

Supply Chain Risks

• Geopolitical Factors: Reliance on API from specific regions can expose the supply chain to risks from trade disputes, natural disasters, or political instability.
• Raw Material Availability: The synthesis of nitrofurantoin involves various chemical precursors. Disruptions in the supply of these raw materials can impact API production.
• Quality Incidents: Recalls or quality issues with an API supplier can lead to significant disruptions for drug manufacturers, necessitating rapid supplier qualification and transition.

Dual Sourcing Strategy: To mitigate supply chain risks, pharmaceutical companies often adopt a dual sourcing strategy, engaging with at least two qualified API manufacturers. This ensures continuity of supply in case of unforeseen events affecting a primary supplier.

Comparative Analysis of API Sourcing Options

When selecting an API supplier for nitrofurantoin, companies must weigh several factors to ensure product quality, regulatory compliance, and cost-effectiveness.

Factor	High-Tier Suppliers (e.g., Major Indian/Chinese Manufacturers)	Mid-Tier Suppliers	Niche/Emerging Suppliers
Manufacturing Scale	High, established capacity to meet large volume demands.	Moderate, may serve specific market segments or smaller volumes.	Varies, often smaller scale initially.
Regulatory Track Record	Strong, well-established DMFs, history of successful FDA/EMA inspections.	Developing, may have DMFs but less extensive inspection history.	New or limited, requires extensive due diligence.
Quality Control Systems	Robust, comprehensive QC/QA, validated analytical methods.	Adequate, may require more detailed scrutiny of validation packages.	Basic to developing, requires thorough evaluation.
Cost	Competitive due to scale and regional cost advantages.	Moderate, may offer price differentiation.	Variable, can be higher due to smaller scale or specialized processes.
Supply Chain Reliability	Generally high, but subject to broader market risks.	Moderate, may have more localized supply chain dependencies.	Potentially less reliable due to less established infrastructure.
Technical Support	Experienced teams, responsive to customer inquiries.	Competent, may be less specialized.	Limited, may require more internal expertise for integration.

Strategic Sourcing Decision: For critical products like Macrobid, a strategic sourcing decision involves not only cost but also the supplier's long-term viability, regulatory compliance, and ability to consistently deliver high-quality API. Companies should perform thorough due diligence, including site audits and review of quality agreements, before establishing a supply relationship.

Key Takeaways

• Nitrofurantoin macrocrystals, the API in Macrobid, are produced by a limited number of global API manufacturers, primarily located in India and China.
• While the nitrofurantoin molecule is off-patent, specific macrocrystalline forms and manufacturing processes have been protected, influencing generic market entry.
• Regulatory compliance with GMP, robust DMFs, and successful agency inspections are non-negotiable requirements for API suppliers.
• Supply chain risks include geopolitical factors, raw material availability, and potential quality incidents.
• A dual sourcing strategy is recommended for supply chain resilience.

Frequently Asked Questions

1. What is the primary difference in API production between nitrofurantoin monohydrate and nitrofurantoin macrocrystals? Nitrofurantoin macrocrystals are produced through a specialized controlled crystallization process that yields larger, more uniform crystals compared to the monohydrate form. This process aims to alter dissolution characteristics.

2. Are there any active patents that prevent the manufacture of nitrofurantoin macrocrystals by generic API producers? Key patents covering the macrocrystalline form and early manufacturing processes have expired, allowing for generic competition. However, ongoing patent filings for novel synthetic routes or improved manufacturing techniques may still exist and require analysis.

3. What are the critical quality attributes for nitrofurantoin macrocrystals as an API? Critical quality attributes include particle size distribution, crystalline morphology, purity (especially concerning specific impurities), potency, and dissolution profile.

4. How does the regulatory status of an API supplier affect drug product approval? The regulatory status of an API supplier, evidenced by their DMF filing and inspection history with agencies like the FDA and EMA, is crucial. A compliant supplier is essential for the approval and continued marketing of the finished drug product.

5. What is the typical lead time for qualifying a new nitrofurantoin API supplier? Qualifying a new API supplier typically involves extensive due diligence, including site audits, quality agreement finalization, and potentially process validation batches. This process can range from 6 to 18 months, depending on the complexity and the supplier's readiness.

Citations

[1] B. C. V. S. Rao, V. L. V. Swamy, & S. V. V. Rao (2012). Nitrofurantoin: A Critical Review of its Pharmacology and Clinical Uses. International Journal of Pharmaceutical Sciences and Research, 3(8), 2650-2665.